

Supplementary Figure S4. RHOA activation is required for the maintenance of NSCLC cells expressing mutant KRAS. (A) Immunoblot showing total (PARP) and cleaved PARP (ΔPARP) in NSCLC cells treated as indicated. The genotypes of the cells

are indicated. Mut: mutant. Wt: wild type. **(B)** Histogram showing viability of the indicated NSCLC cells 120h after transfection with RHOA or control siRNAs. The mutation status of the cell lines is indicated. Mut: mutant. Wt: wild type. **(C)** Immunoblot showing total ERK1/2 and p-ERK1/2 in HBEC3KT cells transduced with pBabePuro-$KRAS^{G12V}$ and/or an shRNA against p53. **(D)** G-LISA assay showing RHOA-GTP levels in HBEC3KT cells transduced as indicated. Mean ± s.e.m. **P*<0.03. **(E)** Upper panel: histograms showing viability of HBEC3KT cells transduced as indicated and transfected with RHOA or control siRNAs. The relative viability was calculated 72h after siRNA transfection. Mean ± s.e.m. ***P*<0.007. Lower panel: Immunoblot showing RHOA knockdown efficiency. Every lane matches the corresponding column of the histogram above. **(F)** G-LISA assay showing RHOA-GTP levels of A549 cells transduced as indicated, either before implantation in athymic nude mice or in excised tumors. Mean ± s.d. **P*<0.05.